UroGen Pharma (URGN) Operating Income Growth (3y) (2020 - 2026)

UroGen Pharma (URGN) Operating Income Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 16.96%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -12.10%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 UroGen Pharma 2.07 Bn 1.93 Bn 46.82 Mn 2.77%

Historic Data

Download Data
DateValue
Mar 31, 2026 2.77%
Dec 31, 2025 1.96%
Sep 30, 2025 -14.83%
Jun 30, 2025 -30.35%
Mar 31, 2025 -18.91%
Dec 31, 2024 -11.57%
Sep 30, 2024 9.20%
Jun 30, 2024 -4.22%
Mar 31, 2024 0.48%
Dec 31, 2023 18.77%
Sep 30, 2023 22.61%
Jun 30, 2023 21.50%
Mar 31, 2023 17.00%
Dec 31, 2022 20.15%
Sep 30, 2022 8.30%
Jun 30, 2022 7.64%
Mar 31, 2022 0.71%
Dec 31, 2021 6.05%
Sep 30, 2021 -3.59%
Jun 30, 2021 -7.38%